文献速递前列腺癌前列腺增生与排尿功能障碍

β3肾上腺素能受体激动剂与膀胱过度活动症患者肾癌风险的关系

Impact of β3-adrenergic receptor agonist on kidney cancer risk in patients with overactive bladder.
PubMed 文献 · BJU Int · 2025-05-09

结果显示米拉贝隆组肾癌发生率高于抗胆碱能组,提示β3-AR激动剂使用与肾癌风险增加相关,但需进一步研究确认因果。

要点

  • 米拉贝隆组肾癌发生率为0.7/1000人年,抗胆碱能组为0.5/1000人年。
  • 验证队列中米拉贝隆组肾癌发生率1.8%,高于抗胆碱能组0.7%(P=0.025)。
  • 临床处方米拉贝隆时,对存在肾癌风险因素的患者应谨慎。

核心结论

  • 与抗胆碱能药物相比,使用β3-AR激动剂与肾癌风险增加相关。
  • 米拉贝隆使用与肾癌之间的关联需进一步研究确认因果关系。

研究设计与样本

  • 主要暴露为β3-AR激动剂或抗胆碱能药物摄入,主要结局为肾癌发生率。

主要发现

  • 米拉贝隆组肾癌发生率为0.7/1000人年,抗胆碱能组为0.5/1000人年。
  • 验证数据共3,108例患者(49.3%男性;平均年龄63.9[SD 13.3]岁),45例(1.4%)在OAB治疗后发生肾癌。
  • 验证队列中米拉贝隆组肾癌发生率(1.8%)高于抗胆碱能组(0.7%)(P=0.025)。

临床怎么用

  • 临床医生在为有肾癌风险因素的患者处方米拉贝隆时应谨慎。

局限性

  • 研究结果为观察性关联,需进一步研究确认因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine the effect of β3-adrenergic receptor (AR) agonist on the risk of kidney cancer in patients with overactive bladder (OAB). PATIENTS AND METHODS: A nationwide population cohort study was conducted using data from the Korean National Health Insurance System database between January 2016 and December 2023. Validation analyses were performed using clinical data from patients with OAB treated with mirabegron or anticholinergics at a tertiary referral hospital between January 2014 and December 2023. The main exposure was intake of β3-AR agonist or anticholinergics, and the main outcome was incidence of kidney cancer. RESULTS: Of the 1 419 148 patients (61.6% male; median [interquartile range] age, 64 [53-73] years), 3229 developed kidney cancer after OAB treatment. The incidence rate of kidney cancer was 0.7 per 1000 person-years in the mirabegron group and 0.5 per 1000 person-years in the anticholinergic group. Among the validation data of 3108 patients (49.3% male; mean [standard deviation] age, 63.9 [13.3] years), 45 (1.4%) developed kidney cancer after OAB treatment. The mirabegron group had a higher incidence of kidney cancer (1.8%) than the anticholinergic group (0.7%) (P = 0.025). CONCLUSIONS: Use of β3-AR agonists was associated with an increased risk of kidney cancer compared with anticholinergics. While these findings suggest a potential association between mirabegron use and kidney cancer, further studies are needed to confirm causality. Clinicians should exercise caution when prescribing mirabegron in patients with risk factors for kidney cancer.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Park JS, Choi SB, Kim J, et al. Impact of β3-adrenergic receptor agonist on kidney cancer risk in patients with overactive bladder. BJU Int. 2025. PMID: 40344609. doi:10.1111/bju.16771

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。